| No images? Click here  Tuesday, 31 October 2024 MEDIA ADVISORY Virtual press conference on global health issues When: Friday, November 1 at 1500 CET(Geneva time) Hosted by: Dr Tedros Adhanom Ghebreyesus, Director-General Subject: Global health issues Connect by Zoom: https://who.zoom.us/j/98397582872 Password: WHO11%1vpc Telephone; International numbers available: https://who.zoom.us/u/az3ef0nSL Webinar ID: 983 9758 2872 Password: 7385340619 Join by SIP Notes to journalists: Please ensure you enter your name and media outlet (use name/outlet). Kindly note, only questions from media (one per journalist) are allowed. When you sign in you will be automatically put in the meeting room. WHO reserves the right to remove any participant whose behaviour causes any disruption. The event is also broadcast on WHO social media channels and you can follow it there.To ask a question, please click "raise hand" and this will enter you into the queue for questions (it can be found under the tab: participants).Please make sure you have a microphone connected or active on your computer. Do not ask questions via the chat as we cannot guarantee that we can incorporate them into the Q&A session. Media contacts:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
Thursday, October 31, 2024
MEDIA ADVISORY: Virtual press conference on global health issues - Friday, November 1 at 1500(Geneva time)
Wednesday, October 30, 2024
News Release: WHO lists additional mpox diagnostic tests for emergency use
| No images? Click here  Wednesday, 30 October 2024 News Release WHO lists additional mpox diagnostic tests for emergency use As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure. WHO’s EUL is based on the review of quality, safety and performance data in compliance with international standards while addressing the specific needs of low- and middle-income countries (LMICs). Polymerase Chain Reaction (PCR) testing, which detects viral DNA, is considered the gold standard for diagnosing mpox infection. WHO listed the Xpert Mpox, a real-time PCR test manufactured by Cepheid under its EUL procedure, on 25 October. This test is designed for use on compatible GeneXpert systems. The Xpert Mpox test is easy to operate and delivers results in under 40 minutes. Once the cartridge is placed in the system, the process is fully automated, with real-time PCR detecting viral DNA of monkeypox virus clade II. The GeneXpert system is a near-point-of-care testing option, which can support decentralized testing. Another PCR-based option, the cobas MPXV assay, developed by Roche Molecular Systems, Inc., was listed on 14 October 2024. It is intended for use on the cobas 6800/8800 Systems. This tool is a real-time PCR test capable of detecting both mpox clades and delivering results in under 2 hours. It can process multiple samples simultaneously and is suitable for clinical laboratories that handle large volumes of tests. “Ensuring global access to mpox diagnostic tests that meet WHO standards for quality, safety and performance is essential for efficient and effective testing in settings affected by mpox outbreaks,” said Dr Rogerio Gaspar, WHO Director for Regulation and Prequalification. “Rapid access to those listed products is critical not only for prompt diagnosis and timely treatment but also for effectively containing the spread of the virus." WHO previously listed Alinity m MPXV assay, manufactured by Abbott Molecular Inc. under EUL on 3 October. In 2024, 18 countries have reported over 40 000 suspected mpox cases with most remaining unconfirmed due to limited testing capacity, especially in LMICs. In the Democratic Republic of the Congo—the hardest-hit country—testing has significantly increased in 2024, following efforts to decentralize testing with support from WHO and partners. However, the proportion of tested cases remains low, accounting for 40-50% of the suspected cases. WHO is working with manufacturers of the EUL-listed products and national regulatory authorities in affected countries to facilitate domestic registration or emergency listing. Fast-tracking approvals and applying reliance principles will enhance access to quality-assured mpox tests. Overall, WHO has received over 60 expressions of interest for the EUL review of mpox diagnostic tests. Seven of these progressed to EUL applications, with 2 products currently under review and 2 more expected soon. The status of active applications and listed mpox diagnostics under WHO EUL procedure can be seen on WHO webpages. Editor’s note After WHO Director-General Dr Tedros Adhanom Ghebreyesus declared mpox a public health emergency of international concern (PHEIC) on 14 August 2024, WHO called on mpox in vitro diagnostic manufacturers to submit expressions of interest for Emergency Use Listing on 28 August 2024. WHO EUL is a risk-benefit assessment designed to meet urgent needs during public health emergencies based on limited available data, accelerating the availability of life-saving medical products such as vaccines, tests, and treatments. It assists decision-making for procurement by UN, partner agencies and Member States at international, regional and national levels. Under EUL, the manufacturers must commit to continue generating any missing information in order to fulfil prequalification requirements. Once this information is available, a prequalification application should be submitted to complete the full process for achieving a recommendation for international procurement in both emergency and non-emergency settings.  WHO media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
Tuesday, October 29, 2024
News Release: Tuberculosis resurges as top infectious disease killer
| No images? Click here  Tuesday, 29 October 2024 News Release Tuberculosis resurges as top infectious disease killer29 October 2024/Washington D.C., USA -- The World Health Organization (WHO) today published a new report on tuberculosis revealing that approximately 8.2 million people were newly diagnosed with TB in 2023 – the highest number recorded since WHO began global TB monitoring in 1995. This represents a notable increase from 7.5 million reported in 2022, placing TB again as the leading infectious disease killer in 2023, surpassing COVID-19. WHO’s Global Tuberculosis Report 2024 highlights mixed progress in the global fight against TB, with persistent challenges such as significant underfunding. While the number of TB-related deaths decreased from 1.32 million in 2022 to 1.25 million in 2023, the total number of people falling ill with TB rose slightly to an estimated 10.8 million in 2023. With the disease disproportionately affecting people in 30 high-burden countries, India (26%), Indonesia (10%), China (6.8%), the Philippines (6.8%) and Pakistan (6.3%) together accounted for 56% of the global TB burden. According to the report, 55% of people who developed TB were men, 33% were women and 12% were children and young adolescents. “The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it and treat it,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “WHO urges all countries to make good on the concrete commitments they have made to expand the use of those tools, and to end TB.” In 2023, the gap between the estimated number of new TB cases and those reported narrowed to about 2.7 million, down from COVID-19 pandemic levels of around 4 million in 2020 and 2021. This follows substantial national and global efforts to recover from COVID-related disruptions to TB services. The coverage of TB preventive treatment has been sustained for people living with HIV and continues to improve for household contacts of people diagnosed with TB. However, multidrug-resistant TB remains a public health crisis. Treatment success rates for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) have now reached 68%. But, of the 400 000 people estimated to have developed MDR/RR-TB, only 44% were diagnosed and treated in 2023. Funding gaps and challengesGlobal funding for TB prevention and care decreased further in 2023 and remains far below target. Low- and middle-income countries (LMICs), which bear 98% of the TB burden, faced significant funding shortages. Only US$ 5.7 billion of the US$ 22 billion annual funding target was available in 2023, equivalent to only 26% of the global target. The total amount of international donor funding in LMICs has remained at around US$ 1.1–1.2 billion per year for several years. The United States government remains the largest bilateral donor for TB. While the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) contribution to international funding of the TB response, especially in LMICs, is important, it remains insufficient to cover essential TB service needs. The report emphasizes that sustained financial investment is crucial for the success of TB prevention, diagnosis, and treatment efforts. Globally, TB research remains severely underfunded with only one-fifth of the US$ 5 billion annual target reached in 2022. This impedes the development of new TB diagnostics, drugs, and vaccines. WHO continues leading efforts to advance the TB vaccine agenda, including with the support of the TB Vaccine Accelerator Council launched by the WHO Director-General. Complex drivers of the epidemicFor the first time, the report provides estimates on the percentage of TB-affected households that face catastrophic costs (exceeding 20% of annual household income) to access TB diagnosis and treatment in all LMICs. These indicate that half of TB-affected households face such catastrophic costs. A significant number of new TB cases are driven by 5 major risk factors: undernutrition, HIV infection, alcohol use disorders, smoking (especially among men), and diabetes. Tackling these issues, along with critical determinants like poverty and GDP per capita, requires coordinated multisectoral action. “We are confronted with a multitude of formidable challenges: funding shortfalls and catastrophic financial burden on those affected, climate change, conflict, migration and displacement, pandemics, and drug-resistant tuberculosis, a significant driver of antimicrobial resistance,” said Dr Tereza Kasaeva, Director of WHO’s Global Tuberculosis Programme. “It is imperative that we unite across all sectors and stakeholders, to confront these pressing issues and ramp up our efforts.” Global milestones and targets for reducing the TB disease burden are off-track, and considerable progress is needed to reach other targets set for 2027 ahead of the second UN High-Level Meeting. WHO calls on governments, global partners, and donors to urgently translate the commitments made during the 2023 UN High-Level Meeting on TB into tangible actions. Increased funding for research, particularly for new TB vaccines, is essential to accelerate progress and achieve the global targets set for 2027.  WHO media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
News Release: WHO and partners activate Global Health Emergency Corps for the first time in response to mpox outbreak
| No images? Click here  Tuesday, 29 October 2024 News Release WHO and partners activate Global Health Emergency Corps for the first time in response to mpox outbreak29 October 2024 Geneva, Switzerland--In October 2024, WHO and partners, in collaboration with Member States, activated the Global Health Emergency Corps (GHEC) for the first time to provide support to countries facing mpox outbreaks. GHEC is a grouping of professionals with the objective of strengthening the response to health emergencies, and a collaboration platform for countries and health emergency networks. It supports countries on their health emergency workforce, the surge deployment of experts and the networking of technical leaders. GHEC was established by WHO in 2023 after the response to the COVID-19 pandemic revealed the need to streamline efforts of existing networks to ensure better-coordinated support to countries. “WHO and partners are supporting the government of the Democratic Republic of the Congo and other countries to implement an integrated approach to case detection, contact tracing, targeted vaccination, clinical and home care, infection prevention and control, community engagement and mobilization, and specialized logistical support,” said Dr Mike Ryan, Executive Director of WHO’s Health Emergencies Programme. “The GHEC enhances the ability of the many effective responders at national and regional levels to collaborate and ensure the success on the ground in interrupting transmission and reducing suffering.” The first activation of this new support mechanism follows the declaration of mpox as a public health emergency of international concern by WHO Director-General Dr Tedros Adhanom Ghebreyesus on 14 August 2024. Eighteen African countries have reported mpox cases this year, and the rapid spread of clade 1b mpox to at least two other regions has raised concerns about further spread. In collaboration with the International Association of National Public Health Institutes, GHEC is assessing the emergency workforce capacities in 8 countries affected by the mpox outbreak, including the Democratic Republic of the Congo and Burundi, the two most affected countries. The assessment has so far identified 22 areas that need strengthening, including epidemiology and surveillance, laboratory capacities, infection prevention and control, risk communication and community engagement. In the Democratic Republic of the Congo, the Health Cluster partners have joined in strengthening the coordination set up by the Ministry of Health under the leadership of the public health emergency operations centre. As of 17 October, WHO has managed the deployment of 56 experts to the affected countries. This includes WHO staff as well as experts mobilized through the Global Outbreak Alert and Response Network (GOARN) and the African Volunteers Health Corps (AVoHC-SURGE). The AVoHC-SURGE responders, coordinated by WHO’s Regional Office for Africa and the Africa Centres for Disease Control and Prevention, are a growing cohort of professionals with diverse skillsets that can be deployed in the region. “By mobilizing trained professionals from within the continent, we ensure that responses are not only timely but also contextually relevant,” said Dr Abdou Salam Gueye, Regional Emergency Director for the WHO Regional Office for Africa. “The dedication and expertise of these responders are essential in saving lives and building resilient health systems capable of withstanding future threats.” Additionally, GOARN is leading the efforts to map the support provided by partners on a bilateral basis to affected countries and the regional coordination structure. This includes the provision of experts, supplies, financial support, capacity strengthening and other activities. As part of the GHEC activation, on 22 October, technical leaders from affected countries and leaders from other countries, including those who have experienced previous mpox outbreaks, convened to discuss the most effective control measures, share best practices and coordinate their efforts to halt the outbreak. Note to editors: GHEC was established by WHO in 2023 in response to the gaps and challenges identified during the COVID-19 response. It supports countries experiencing public health emergencies through three key pillars:
 WHO media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
JOINT STATEMENT: What are healthy diets? Joint statement by the Food and Agriculture Organization of the United Nations and the World Health Organization
| No images? Click here  Tuesday, 29 October 2024 What are healthy diets? Joint statement by the Food and Agriculture Organization of the United Nations and the World Health Organization24 October 2024| Publication OverviewHealthy diets promote health, growth and development, support active lifestyles, prevent nutrient deficiencies and excesses, communicable and noncommunicable diseases, foodborne diseases and promote wellbeing. The exact make-up of a diet will vary depending on individual characteristics, preferences and beliefs, cultural context, locally available foods and dietary customs. However, the basic principles of what constitutes healthy diets remain the same. In this document the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) have formulated principles of what constitute healthy diets, underpinned by guidelines and other normative elements developed by the two Organizations. The principles provide the basis for the design of policies aimed at improving diet and for the assessment of the healthiness of diets.
 WHO media contact:  You are receiving this NO-REPLY email because you are included on a WHO mail list.  |
